The global coronary stents market size was USD 9.21 billion in 2023, calculated at USD 9.76 billion in 2024 and is expected to reach around USD 17.40 billion by 2034, expanding at a CAGR of 6% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Coronary Stents Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Coronary Stents Market, by Product, 2024-2034
8.1.1. Bare Metal Stents
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Bioresorbable Vascular Scaffold
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Drug Eluting Stents
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Biodegradable
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Non-Biodegradable
8.1.5.1. Market Revenue and Forecast (2021-2034)
9.1. Coronary Stents Market, by Deployment, 2024-2034
9.1.1. Self-Expandable
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Balloon expandable
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Coronary Stents Market, by Biomaterial, 2024-2034
10.1.1. Metallic Biomaterials
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Polymers Biomaterials
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Natural Biomaterials
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. Coronary Stents Market, by End User, 2024-2034
11.1.1. Hospitals and surgical centers
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Specialty clinics
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.1.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.1.4. Market Revenue and Forecast, by End User (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.2.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.2.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End User (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.3.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.3.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End User (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.4.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.4.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End User (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.5.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Deployment (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Biomaterial (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End User (2021-2034)
13.1. Medtronic plc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Cook Medical
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. B. Braun Melsungen AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Terumo Corporation
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Vascular Concepts
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. STENTYS SA
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. MicroPort Scientific Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Meril Life Sciences Pvt. Ltd
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Translumina
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Biosensors International Group Limited
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample